WHWK insider transaction filings
Whitehawk Therapeutics, Inc. — 39 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-30. Screen WHWK transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-30 | 4 | Dalal Anupam — Director | Grant/award (A): 1,275,510 @ $3.92 · Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Zhao Baiteng — Director | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Desai Neil — Director | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Aghazadeh Behzad — Director, 10% owner Avoro Capital Advisors LLC — Director, 10% owner Avoro Ventures LLC — Director, 10% owner | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Reeve Emma — Director | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Hirmand Mohammad — Director | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Maroun Richard E — Director | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Castelein Caley — Director | Grant/award (A): 38,040 (derivative) @ $0 | EDGAR |
| 2026-05-18 | 4 | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 51,021 @ $3.92 | EDGAR |
| 2026-05-18 | 4 | Dugan Margaret — Chief Medical Officer | Grant/award (A): 19,132 @ $3.92 | EDGAR |
| 2026-05-18 | 4 | BALL BRYAN — See remarks | Grant/award (A): 51,020 @ $3.92 | EDGAR |
| 2026-05-18 | 4 | Giacobello Scott M. — CHIEF FINANCIAL OFFICER | Grant/award (A): 38,265 @ $3.92 | EDGAR |
| 2026-05-18 | 4 | Castelein Caley — Director | Grant/award (A): 255,102 @ $3.92 · Grant/award (A): 2,072,756 (derivative) @ $8,124,996.24 | EDGAR |
| 2026-05-14 | 4 | Avoro Capital Advisors LLC — Director, 10% owner Aghazadeh Behzad — Director, 10% owner Avoro Ventures LLC — Director, 10% owner | Grant/award (A): 6,377,714 (derivative) @ $3.92 | EDGAR |
| 2026-04-17 | 4 | Giacobello Scott M. — CHIEF FINANCIAL OFFICER | Sale (S): 77,000 @ $3.86 · Sale (S): 141,600 @ $4.13 | EDGAR |
| 2026-04-15 | 4 | BALL BRYAN — See remarks | Sale (S): 26,389 @ $3.46 · Sale (S): 92,460 @ $3.64 | EDGAR |
| 2026-04-13 | 4 | BALL BRYAN — See remarks | Sale (S): 50,000 @ $3.57 · Sale (S): 6,596 @ $3.43 | EDGAR |
| 2026-04-10 | 4 | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Sale (S): 14,500 @ $3.38 | EDGAR |
| 2026-04-08 | 4 | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Sale (S): 102,395 @ $3.51 · Sale (S): 94,087 @ $3.43 · Sale (S): 63,945 @ $3.40 | EDGAR |
| 2026-04-03 | 4 | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 775,828 · Sale (S): 26,858 @ $3.48 · Option exercise (M): 775,828 (derivative) @ $0 · Grant/award (A): 831,148 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Dugan Margaret — Chief Medical Officer | Grant/award (A): 283,157 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Dornan David — Chief Scientific Officer | Grant/award (A): 282,340 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | BALL BRYAN — See remarks | Option exercise (M): 366,532 · Option exercise (M): 366,532 (derivative) @ $0 · Grant/award (A): 250,058 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Giacobello Scott M. — CHIEF FINANCIAL OFFICER | Option exercise (M): 473,902 · Option exercise (M): 473,902 (derivative) @ $0 · Grant/award (A): 300,677 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Option exercise (M): 16,250 · Sale (S): 5,100 @ $3.31 · Option exercise (M): 16,250 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | BALL BRYAN — See remarks | Option exercise (M): 5,000 · Sale (S): 1,834 @ $3.31 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-03-10 | 4 | Giacobello Scott M. — CHIEF FINANCIAL OFFICER | Option exercise (M): 6,750 · Sale (S): 2,594 @ $3.31 · Option exercise (M): 6,750 (derivative) @ $0 | EDGAR |
| 2025-12-02 | 4 | Dugan Margaret — Chief Medical Officer | Grant/award (A): 650,000 (derivative) @ $0 · Grant/award (A): 55,309 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | Zhao Baiteng — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | Desai Neil — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Hirmand Mohammad — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Reeve Emma — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Dalal Anupam — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Aghazadeh Behzad — Director, 10% owner Avoro Capital Advisors LLC — Director, 10% owner Avoro Ventures LLC — Director, 10% owner | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Maroun Richard E — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Castelein Caley — Director | Grant/award (A): 40,006 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | BALL BRYAN — See remarks | Grant/award (A): 366,532 (derivative) @ $0 · Grant/award (A): 366,532 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Giacobello Scott M. — CHIEF FINANCIAL OFFICER | Grant/award (A): 473,902 (derivative) @ $0 · Grant/award (A): 473,902 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | Lennon David James — CHIEF EXECUTIVE OFFICER, Director | Grant/award (A): 775,828 (derivative) @ $0 · Grant/award (A): 775,828 (derivative) @ $0 | EDGAR |
Recent 8-K events — Whitehawk Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-21 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-13 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-05-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=WHWK returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →